Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Supplement Review Timeline Hinges On Need For Inspection

Executive Summary

FDA notes that it may not be evident right away whether an inspection will be required as part of the review.

You may also be interested in...



FDA Outlines Criteria For Approving Manufacturing Supplements Under GDUFA

Generic drug manufacturers are told by FDA when and how it will accept prior approval supplements under GDUFA.

Foreign Regulator Training Only Provides Short-Term Gains, FDA Official Says

Acting Deputy Commissioner John Taylor says training often is for reactive work, and FDA must shift to a more proactive strategy and ensure strong regulatory laws, equipment and organizations around the world.

Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.

Topics

UsernamePublicRestriction

Register

PS056265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel